drugset
drugset / Trial / NCT05070195

A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects

NCT05070195 ↗

Phase 1 Completed 14 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label phase I clinical study to investigate the effect of SKLB1028 on the pharmacokinetics of Midazolam and its metabolite 1'-OH-midazolam in healthy subjects. This study also aims to evaluate the safety and tolerability of SKLB1028 in the presence of Midazolam.

Timeline

Start
2021-06-07
Primary completion
2021-07-09
Completion
2021-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 15 mg Oral
Subject RUSERONTINIB Small molecule 150 mg Oral

Indications

No indication recorded.